Advanced Solid Tumors | Norton Healthcare

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Indication: Advanced Solid Tumors

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study

Sub-indication: Miscellaneous Malignancies

Study Type: Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: Sponsor: OncoC4, Inc

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Advanced Solid Tumors Clinical Trial

Schedule an Appointment